Drugs / AdaptNK
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07591649 | May 2026 → Mar 2030 expected | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdaptNK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07591649 ↗ |
| Modality | Cell therapy | “allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK)” NCT07591649 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT07591649 ↗ |